|
gptkbp:instanceOf
|
gptkb:antiretroviral_therapy
gptkb:protease_inhibitor
|
|
gptkbp:approvalYear
|
1999
|
|
gptkbp:ATCCode
|
J05AE05
|
|
gptkbp:brand
|
gptkb:Agenerase
|
|
gptkbp:CASNumber
|
161814-49-9
|
|
gptkbp:category
|
sulfonamides
HIV protease inhibitors
withdrawn drugs
|
|
gptkbp:contraindication
|
hypersensitivity
severe hepatic impairment
|
|
gptkbp:developedBy
|
GlaxoSmithKline
|
|
gptkbp:eliminationHalfLife
|
7-10 hours
|
|
gptkbp:hasMolecularFormula
|
C25H35N3O6S
|
|
gptkbp:hasSMILES
|
CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](Cc2ccccc2)NS(=O)(=O)C)O
|
|
gptkbp:KEGGID
|
D00299
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
HIV-1 protease inhibition
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:proteinBinding
|
90%
|
|
gptkbp:PubChem_CID
|
65016
58532
CHEMBL122
DB00701
|
|
gptkbp:replacedBy
|
gptkb:Fosamprenavir
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
rash
oral paresthesia
|
|
gptkbp:synonym
|
gptkb:141W94
gptkb:VX-478
|
|
gptkbp:UNII
|
Q3JTX2Q7TU
|
|
gptkbp:usedFor
|
HIV infection
|
|
gptkbp:withdrawn
|
2004
|
|
gptkbp:bfsParent
|
gptkb:J05AE
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Amprenavir
|